Clinical Trial: Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome

Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Contribution of a GLP-1 Agonist to Appetite Regulation, Metabolism and Body Composition in Subjects With Prader-Willi Syndrome.

Brief Summary: The purpose of this study is to investigate the effects of a GLP-1 agonist on satiety hormones in patients with Prader-Willi Syndrome (genetic defect causing obesity).

Detailed Summary: Prader-Willi Syndrome (PWS) is the most frequent known genetic disorder of obesity. Hyperphagia is the main barrier to independent living in adults with PWS, and hitherto behavioural restraints and environmental modification are the only effective management measure. The emerging costs for professional care are immense. Thus, there is an urgent need for treatment which reduce appetite and food intake in this patient group. Agonists of the gut derived hormone GLP-1 which reduces food intake and causes weight loss due to slowed gastric emptying and through direct central effects. The aim of this pilot drug trial is to analyse the effect of a GLP-1 agonist on appetite regulating hormones, insulin secretion and energy expenditure before and after a meal.
Sponsor: Garvan Institute of Medical Research

Current Primary Outcome: satiety hormones [ Time Frame: 1 day ]

Original Primary Outcome: Same as current

Current Secondary Outcome: appetite (visual analogue scale) insulin secretion [ Time Frame: 1 day ]

Original Secondary Outcome: Same as current

Information By: Garvan Institute of Medical Research

Dates:
Date Received: October 29, 2007
Date Started: October 2007
Date Completion: September 2008
Last Updated: October 29, 2007
Last Verified: October 2007